Dr. Reddy's Laboratories has been cleared by a U.S. court to sell a generic version of sanofi-aventis' Allegra D-24 allergy medication.


Dr. Reddy's, Allegra D-24, fexofenadine, fexofenadine hydrochloride/pseudoephedrine hydrochloride, allergy medication, sanofi-aventis, Albany Molecular Research, U.S. District Court of New Jersey, injunction, generic, generic allergy drug




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Court clears Dr. Reddy's to market Allegra 24-hour generic

January 31st, 2011

HYDERABAD, India – Dr. Reddy's Laboratories has been cleared by a U.S. court to sell a generic version of sanofi-aventis' Allegra D-24 allergy medication.

The India-based pharmaceutical company said late Sunday that the U.S. District Court of New Jersey on Jan. 28 lifted an earlier motion for a preliminary injunction and cleared Dr. Reddy's to sell its fexofenadine hydrochloride/pseudoephedrine hydrochloride 180 mg/240 mg extended-release tablets.

Dr. Reddy's reported that its generic product, which treats allergy symptoms and congestion, was approved by the Food and Drug Administration last March.

In addition, Dr. Reddy's said that plaintiffs sanofi-aventis and Albany Molecular Research have been required to post a $40 million security with the court toward the possibility that the injunction had been wrongfully granted.

Dr. Reddy's added that it aims to pursue an award of that security, saying that it has been prevented from launching the generic allergy drug since the court imposed the injunction last June.

Advertisement